Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASC30_48FDC
- Development stage
- Unknown
- Lead developer
- Ascletis Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ASC30_48FDC is a small molecule fixed-dose combination (FDC) dual agonist targeting the glucagon-like peptide-1 receptor (GLP-1R) and the gastric inhibitory polypeptide receptor (GIPR). Developed by Ascletis (歌礼生物科技), this therapeutic candidate is currently in the discovery phase for the treatment of obesity. The drug is designed to simultaneously activate both GLP-1 and GIP receptors to leverage synergistic effects on appetite regulation and metabolic control for weight management. As a small molecule formulation, it is intended to provide a potentially more convenient alternative to injectable peptide-based dual agonists.
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on ASC30_48FDC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASC30_48FDC.